Arendt Launches AVA, Its Proprietary AI-powered Prospectus Compliance Review Tool
29.7.2026 15:54:00 EEST | Business Wire | Press release
Arendt & Medernach, the leading independent Luxembourg-based law firm specialising in business law, investment funds, corporate law and tax, announced the launch of AVA (Arendt Visa Agent), a proprietary, purpose-built AI solution designed for UCITS prospectus compliance review. Developed in-house and built on Arendt's own legal knowledge and methodology, with the technical architecture delivered in close collaboration with a specialist AI technology partner, AVA marks a key milestone in Arendt's innovation strategy and reinforces its commitment to leveraging advanced technology to support its clients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729264434/en/
The scale of the challenge
Arendt has developed AVA, an AI-driven compliance tool that draws on the firm's unparalleled market intelligence in UCITS – built over decades of advising fund managers, boards and service providers on Luxembourg's most complex prospectus structures. By translating this accumulated expertise into a comprehensive, machine-readable control framework, AVA enables a more efficient, consistent and scalable approach to prospectus compliance reviews.
Fund managers, boards and other service providers face increasing pressure to manage the cost and timing of compliance-driven legal work, without compromising the quality, consistency or robustness of the review. AVA directly addresses this challenge.
A tool built from the ground up
Rather than relying on an off-the-shelf solution, AVA is the result of an intensive development journey combining Arendt's longstanding experience in UCITS prospectus reviews with advanced AI capabilities. Over many years, Arendt has accumulated substantial legal and regulatory knowledge in this area. This knowledge has been structured, translated into a comprehensive library of controls and adapted for use within AVA's review framework.
For the board of directors of a SICAV, prospectus compliance is not merely a regulatory formality – it is a matter of direct legal responsibility. Directors bear personal accountability for the accuracy and completeness of the prospectus, and any deficiency may engage their liability towards investors and regulators alike. AVA, combined with Arendt's compliance certificate, provides boards with a structured, auditable and documented basis for discharging that responsibility with confidence.
Human expertise in the loop
AVA is designed as a human-in-the-loop solution. Arendt's lawyers remain at the centre of every review: they determine the scope of the exercise, instruct and supervise the analysis, assess the results and exercise independent professional judgement on the conclusions.
AVA supports this process by structuring the review and generating a detailed compliance report. Its findings are categorised as Compliant, Non-Compliant, Inconclusive or Not Applicable, enabling lawyers to focus their review on the points requiring legal assessment or further investigation.
This model combines a scalable and traceable analytical process with lawyer-led interpretation and validation.
Where agreed with the client and appropriate in the circumstances, Arendt may issue a compliance certificate addressed to, and intended to be relied upon by, the board of directors. The certificate provides additional legal comfort in relation to the prospectus within the agreed scope of review.
Strict governance and senior oversight
The launch of AVA is supported by a robust governance framework. A dedicated committee of partners, counsels, senior associates and associates oversees all aspects of the tool, including user feedback, regulatory interpretation, and control updates. Clear protocols govern who reviews findings and when, and Arendt's senior lawyers keep ultimate arbitration authority on regulatory positions, including responses to new CSSF guidance. The tool is always supervised by Arendt's professionals; AI remains a tool, not a decision-maker.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260729264434/en/
Contacts
Media
Julien Delpy
Director, Marketing & Communications
Arendt & Medernach
T +352 40 78 78 2125
julien.delpy@arendt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Multi-Orbit Satellite Connectivity on LATAM Airbus, Embraer Fleet29.7.2026 18:30:00 EEST | Press release
SES, a leading space solutions company, was selected by LATAM Airlines to provide multi-orbit inflight connectivity service to its growing fleet of Airbus and Embraer aircraft, solidifying SES’s position as the top provider of multi-orbit broadband service in the Americas and around the world. “LATAM’s passengers will soon benefit from reliable, multi-orbit satellite connectivity that will provide the same fast and dependable internet access they enjoy at home no matter where or when they fly. SES’s partnerships with airlines like LATAM highlight how carriers throughout the Americas are leading the way when it comes to the most advanced connectivity. SES is a trusted partner that powers inflight connectivity,” said Mike DeMarco, SES President of Mobility. More than 60 Airbus (A320NEO and A321XLR) and Embraer aircraft (E195-E2) will be equipped with SES services in the coming years. LATAM will be the largest airline in the region to offer service using SES’s new electronically steered a
Carta Rearchitects Private Capital Operations with Plugins for Claude29.7.2026 17:01:00 EEST | Press release
Carta, the connected platform and AI-native ecosystem for private capital, today announces broad availability of its suite of Plugins for Claude following the initial launch in April 2026. With more than 1,500 companies and firms already using the plugins, Carta is changing the way private capital teams — from founders to CFOs — fundamentally operate, bringing fund administration, cap table management, and dealflow analytics directly into the spreadsheets, presentations, and workflows they already use every day. "For the last decade, private capital operation teams have been held back by a hidden tax: the constant, manual handoff of data between disconnected systems," said Henry Ward, Carta CEO. "Carta is eliminating that broken loop entirely by embedding intelligence directly into the tools teams already use. We are not waiting for an AI-native future for private capital — it is running on Carta today." Carta didn't just give Claude a pipe to its data. Carta built its private-capital
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
Grid Dynamics Accelerates Enterprise AI-Native Transformation With Workforce Certification and GAIN Platforms Rollout29.7.2026 16:00:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a leading provider of technology consulting, platform and product engineering, and AI-driven digital transformation services, today announced significant momentum in the adoption of its enterprise agentic AI solutions. Organizations across retail, financial services, manufacturing, CPG, and logistics industries are increasingly deploying Grid Dynamics’ agentic AI-native platforms and Forward Deployed Engineering (FDE)-led services to accelerate software delivery, improve operational efficiency, and transform business processes at scale. Grid Dynamics is widely recognized for its enterprise AI expertise and delivery capabilities across Fortune 1000 organizations. Grid Dynamics has partnership agreements with Anthropic and OpenAI to accelerate the adoption of these platforms within enterprises. By the end of October 2026, Grid Dynamics plans to have 90% of its engineers trained and certified on these platforms. Built to suppo
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom